Antibody construct expression technology
Patent Information
- Application Number
- JP2023530543
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-23
- Filing Date
- 2021-11-22
- Publication Date
- 2024-11-29
AI Technical Summary
Existing methods for producing bispecific antibodies suffer from incorrect assembly, mispairing of light and heavy chains, incomplete constructs, and unbalanced expression of polypeptide chains, leading to reduced yield, purity issues, and increased risk of anti-drug antibodies, especially during large-scale production.
The use of a nucleic acid product encoding antibody constructs with at least three different polypeptide chains, where consecutive chains are connected by a 2A peptide within the same open reading frame, ensuring balanced expression and correct assembly through self-cleaving peptide linkers.
This approach significantly increases the proportion of correctly assembled antibody constructs, enhances yield and purity, and simplifies the purification process by ensuring balanced mRNA and protein levels, reducing undesirable by-products.
Smart Images

Figure 2022107090000001
Abstract
Description
[Technical Field]
[0001] The present invention relates to the field of recombinant protein production. A new expression strategy for antibody constructs is provided. In particular, nucleic acid products for the production of antibody constructs having several different polypeptide chains are provided, where the polypeptide chains are encoded within the same open reading frame, separated by 2A peptides that result in the production of separate polypeptide chains. This allows for uniform expression and correct assembly of the antibody constructs. [Background technology]
[0002] Bispecific antibodies are antibodies that bind to two distinct epitopes. Most commonly, bispecific antibodies are constructed by pairing a heavy chain-light chain pair for a first epitope with another heavy chain-light chain pair for a second epitope. Such antibody constructs are well known in the art. One approach to generating bispecific antibodies is the so-called knob-into-hole (KiH) technique, described, for example, in Ridgway et al. (1996) Protein Engineering 9(7):617-621. Here, a first heavy chain is modified to exhibit a hole-like structure by substituting a larger amino acid for a smaller one, and a second heavy chain is modified to exhibit a knob-like structure at the corresponding site of the heavy chain:heavy chain interface using amino acid substitutions in which a smaller amino acid is replaced with a larger one. Because pairing of the knob heavy chain and the hole heavy chain is favored, bispecific antibodies, i.e., heterotetrameric proteins consisting of two different light chains and two different heavy chains, are formed.
[0003] However, antibody misassembly still occurs in host cells, particularly due to mismatching of a light chain with an incorrect heavy chain, or pairing of two identical heavy chains, or incomplete constructs lacking one polypeptide chain. Furthermore, the polypeptide chains of bispecific antibodies are often expressed at different amounts, for example, because the expression cassettes for the polypeptide chains are expressed at different amounts, leading to unbalanced mRNA levels. This increases the amount of misassembled antibody constructs.
[0004] Misassembled antibodies reduce the overall yield of the production process and are particularly difficult to remove during the purification process.
[0005] Therefore, existing methods for generating bispecific antibodies may not provide sufficient overall yield, purity, and product quality in a cost-effective manner to enable production on a scale feasible for clinical development and commercialization. Furthermore, modifications of the protein chain inherently increase the risk of inducing anti-drug antibodies. Therefore, approaches requiring only minimal protein engineering may be clinically advantageous. Summary of the Invention
[0006] In view of the above, there is a need in the art to provide improved strategies for producing bispecific and other antibody constructs that result in high yields and rates of correctly assembled antibody constructs.
[0007] The present inventors have discovered that antibody constructs containing three or more different polypeptide chains, such as bispecific antibodies or antibody fusion proteins, can be produced with significantly increased efficiency if at least some of the different polypeptide chains are encoded within the same open reading frame using a self-cleaving peptide linker, such as a 2A peptide, between the polypeptide chains. The present inventors have shown that this approach provides balanced expression at the mRNA level, thereby leading to more balanced protein levels. Furthermore, translation of different polypeptide chains from a single mRNA occurs in close proximity within the host cell. This ensures that the produced antibody constructs are correctly assembled, preventing undesired mispairing of polypeptide chains and overproduction of some polypeptide chains. Thus, the present invention provides an increased proportion of correctly formed antibody constructs expressed by host cells, thus increasing the overall yield and purity of the desired product. The present inventors have demonstrated the advantages of the present approach for several different antibody constructs, all of which showed a much higher percentage of correctly assembled protein compared to conventional approaches.
[0008] Thus, in a first aspect, the present invention is directed to a nucleic acid product comprising one or more vector nucleic acids encoding an antibody construct comprising at least three distinct polypeptide chains, wherein the antibody construct comprises an antibody heavy chain, and wherein at least two distinct polypeptide chains of the antibody construct are encoded within the same open reading frame, and wherein consecutive polypeptide chains encoded within said open reading frames are connected by a peptide linker comprising a 2A peptide.
[0009] In a second aspect, the present invention provides a host cell comprising a nucleic acid product according to the first aspect.
[0010] In a third aspect, the present invention provides a method for producing a medicament for the treatment of a pulmonary arthritis, comprising: (a) providing a host cell according to the second aspect; (b) culturing the host cells in cell culture under conditions that allow the production of the antibody construct; (c) obtaining the antibody construct from the cell culture; and (d) Optionally, treating the antibody construct The present invention provides a method for producing an antibody construct, comprising:
[0011] In a fourth aspect, the present invention provides the use of a nucleic acid product according to the first aspect or a host cell according to the second aspect for the production of an antibody construct.
[0012] In a fifth aspect, the present invention provides a method of producing a host cell according to the second aspect, comprising introducing a nucleic acid product according to the first aspect into a host cell.
[0013] Other objects, features, advantages, and aspects of the present invention will become apparent to those skilled in the art from the following description and appended claims. It should be understood, however, that the following description, appended claims, and specific examples, which indicate preferred embodiments of the present application, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following.
[0014] definition As used herein, the following expressions are generally and preferably intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.
[0015] As used herein, the term "comprising" includes and specifically refers to the terms "consisting essentially of" and "consisting of," in addition to its literal meaning. Thus, the term "comprising" refers to embodiments in which the subject matter "comprising" the specifically listed elements does not include additional elements, as well as embodiments in which the subject matter "comprising" the specifically listed elements can and / or does include additional elements. Similarly, the term "having" should be understood as the term "comprising," and also includes and specifically refers to the terms "consisting essentially of" and "consisting of." The term "consisting essentially of," when possible, particularly refers to embodiments in which the subject matter contains no more than 20%, particularly no more than 15%, particularly no more than 10%, or particularly no more than 5% of additional elements in addition to the specifically listed elements from which the subject matter essentially consists.
[0016] The term "nucleic acid" includes single- and double-stranded nucleic acids and ribonucleic acids and deoxyribonucleic acids. It may contain natural and synthetic nucleotides and can be modified naturally or synthetically, for example, by methylation, 5'- and / or 3'-capping. In certain embodiments, nucleic acid refers to double-stranded deoxyribonucleic acid.
[0017] A "nucleic acid product" according to the present invention is a nucleic acid or a set of two or more nucleic acids that together encode a desired polypeptide or protein. In particular, a nucleic acid product encoding a protein composed of two or more different polypeptide chains includes a nucleic acid product consisting of one nucleic acid encoding all of the different polypeptide chains, and a nucleic acid product consisting of two or more different nucleic acids, each of which encodes at least one of the different polypeptide chains, and all of the nucleic acids of the nucleic acid product together encode all of the different polypeptide chains of the protein. The different nucleic acids of the nucleic acid product are usually designed to coordinate with each other. For example, the different nucleic acids can have different selectable markers so that maintenance of each nucleic acid in a transfected host cell can be controlled.
[0018] The term "expression cassette" specifically refers to a nucleic acid construct capable of enabling and regulating the expression of a coding nucleic acid sequence introduced therein. Expression cassettes may include promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation. While the exact structure of an expression cassette may vary as a function of species or cell type, it generally includes 5'-nontranscribed sequences, as well as 5'- and 3'-nontranslated sequences, such as the TATA box, capping sequence, and CAAT sequence, involved in the initiation of transcription and translation, respectively. More specifically, the 5'-nontranscribed expression control sequence includes a promoter region, including a promoter sequence for transcriptional control of an operably linked nucleic acid. Expression cassettes may also include enhancer sequences or upstream activator sequences.
[0019] According to the present invention, the term "promoter" refers to a nucleic acid sequence located upstream (5') of a nucleic acid sequence to be expressed, which controls the expression of the sequence by providing recognition and binding sites for RNA polymerase. A "promoter" may contain additional recognition and binding sites for additional factors involved in regulating gene transcription. A promoter may control the transcription of a prokaryotic or eukaryotic gene. Furthermore, a promoter may be "inducible," i.e., initiate transcription in response to an inducing agent, or "constitutive," if transcription is not controlled by an inducing agent. A gene under the control of an inducible promoter is not expressed or is expressed only weakly in the absence of the inducing agent. In the presence of the inducing agent, the gene is switched on or the level of transcription is increased. This is generally mediated by the binding of specific transcription factors.
[0020] The term "vector" is used herein in its most general sense and includes, for example, any intermediate carrier of nucleic acid that allows said nucleic acid to be introduced into prokaryotic and / or eukaryotic cells and, where appropriate, integrated into the genome. This type of vector is preferably replicated and / or expressed intracellularly. Vectors include plasmids, phagemids, bacteriophages or viral genomes. The term "plasmid" as used herein generally relates to a construct of extrachromosomal genetic material, usually a circular DNA double strand, that can replicate independently of chromosomal DNA. Vectors according to the invention can exist in circular or linear form. As used herein, "vector nucleic acid" is a nucleic acid that forms a vector or a nucleic acid portion of a vector.
[0021] The terms "5'" and "3'" are conventionally used to describe features of nucleic acid sequences related to the location of genetic elements and / or the direction of events (5' to 3'), such as transcription by RNA polymerase proceeding in the 5' to 3' direction, or translation by ribosomes. Synonyms are upstream (5') and downstream (3'). Conventionally, DNA sequences, gene maps, vector cards, and RNA sequences are drawn 5' to 3' from left to right, or the 5' to 3' direction is indicated by an arrow with the arrowhead pointing in the 3' direction. Thus, according to this convention, 5' (upstream) refers to a genetic element located towards the left, and 3' (downstream) refers to a genetic element located towards the right.
[0022] A "polypeptide" or "polypeptide chain" refers to a molecule comprising a polymer of amino acids linked together by peptide bonds. Polypeptides include polypeptides of any length, including proteins (e.g., having more than 50 amino acids) and peptides (e.g., having 2-49 amino acids). In particular, a polypeptide or polypeptide chain can be part of a protein made up of two or more polypeptide chains. Polypeptides include proteins and / or peptides with any activity or biological activity. Polypeptides can be pharmaceutically or therapeutically active compounds or research tools utilized in assays and the like. Suitable examples are outlined below.
[0023] A target amino acid sequence is "derived from" or "corresponding to" a reference amino acid sequence if it shares at least 75%, more preferably at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at least 97%, at least 98%, or at least 99% identity with the reference amino acid sequence over its entire length. In certain embodiments, a target amino acid sequence that is "derived from" or "corresponding to" a reference amino acid sequence is 100% homologous, or particularly 100% identical, to the reference amino acid sequence over its entire length. Similarly, a target nucleotide sequence is "derived from" or "corresponding to" a reference nucleotide sequence if it shares at least 75%, more preferably at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at least 97%, at least 98%, or at least 99% identity with the reference nucleotide sequence over its entire length. In certain embodiments, a target nucleotide sequence that is "derived from" or "corresponding to" a reference nucleotide sequence is 100% identical to the reference nucleotide sequence over its entire length. The "identity" of an amino acid sequence or nucleotide sequence is preferably determined according to the present invention over the entire length of the reference sequence.
[0024] The term "antibody" specifically refers to an antibody protein comprising at least two heavy chains and two light chains connected by disulfide bonds. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH). Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL). The heavy chain constant region comprises three, or in the case of IgM or IgE antibodies, four heavy chain constant domains (CH1, CH2, CH3, and CH4), where the first constant domain CH1 is adjacent to the variable region and may be connected to the second constant domain CH2 by a hinge region. The amino acid sequences of the human CH1, hinge region, CH2, and CH3 of a γ1 heavy chain are set forth in SEQ ID NOs: 1 to 4, respectively, and the entire constant region of a human γ1 heavy chain is set forth in SEQ ID NO: 5. The light chain constant region consists of only one constant domain. The variable region can be further subdivided into hypervariable regions called complementarity-determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs), with each variable region containing three CDRs and four FRs. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The heavy chain constant region can be of any type, such as a gamma, delta, alpha, mu, or epsilon heavy chain. Preferably, the antibody heavy chain is a gamma chain. Furthermore, the light chain constant region can be any type, such as a kappa or lambda light chain. The amino acid sequences of the constant domains CL of human lambda and kappa light chains are set forth in SEQ ID NOs: 6 and 7, respectively. The terms "gamma (delta, alpha, mu, or epsilon) heavy chain" and "kappa (lambda) light chain" refer to antibody heavy chains or antibody light chains, respectively, which have constant region amino acid sequences derived from naturally occurring heavy or light chain constant region amino acid sequences, particularly human heavy or light chain constant region amino acid sequences. The antibody can be, for example, a humanized, human, or chimeric antibody.
[0025] The term "antibody" as used herein also includes fragments, derivatives, and grafts of said antibody. In particular, an antibody "fragment or derivative" is a protein or glycoprotein derived from said antibody and capable of binding to the same antigen, in particular the same epitope as the antibody. In a further embodiment, an antibody "fragment or derivative" refers in particular to a polypeptide or protein comprising one or more Fc regions of an antibody, which may or may not comprise an antigen-binding region. Thus, an antibody fragment or derivative herein generally refers to a functional fragment or derivative whose antibody function is antigen binding and / or interaction with an Fc receptor. An antibody "graft" refers in particular to an antibody in which a heterologous polypeptide is introduced into or (partially) replaces the CDR sequences of the antibody. Exemplary antibody grafts are described in U.S. Patent Application Publication No. 2017 / 0158747A1.
[0026] The term "antibody construct" as used herein refers to any protein comprising at least one protein domain derived from an antibody. In particular, an antibody construct is an artificial protein and may comprise portions of different natural or engineered proteins, including at least one antibody. In particular, an antibody construct comprises at least one immunoglobulin domain derived from an antibody, in particular a human IgG antibody. In certain embodiments, an antibody construct comprises at least a constant immunoglobulin domain derived from an antibody, such as a CH2 domain or a CH3 domain, in particular a CH2 domain and a CH3 domain.
[0027] The cells specifically mentioned herein are host cells. According to the present invention, the term "host cell" relates to any cell that can be transformed or transfected with an exogenous nucleic acid. Particularly preferred are mammalian cells, such as cells from humans, mice, hamsters, pigs, goats, or primates. The cells may be derived from a number of tissue types and include primary cells and cell lines. The nucleic acid may be present in the host cell in the form of a single copy or two or more copies and, in one embodiment, is expressed in the host cell.
[0028] "Uniform production" of a polypeptide chain refers to balanced levels of polypeptide chains encoded within the same open reading frame obtained after translation with balanced levels of the encoding mRNA obtained after transcription.
[0029] The term "pharmaceutical composition" or "pharmaceutical formulation" specifically refers to a composition suitable for administration to a human or animal, i.e., a composition containing pharmaceutically acceptable ingredients. Preferably, a pharmaceutical composition comprises an active compound or a salt or prodrug thereof together with a carrier, diluent, or pharmaceutical excipient such as a buffer, preservative, and isotonicity adjusting agent.
[0030] The values given herein are preferably understood as approximate values, in particular they may preferably be up to 10% higher and / or lower, in particular up to 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% higher and / or lower.
[0031] Numerical ranges described herein are inclusive of the numerical values defining the range. The headings provided herein are not intended to limit the various aspects or embodiments of the present invention, which can be read by reference to the specification as a whole. According to one embodiment, an object described herein as comprising a particular step in the case of a method or a particular component in the case of a composition refers to an object consisting of each step or component. It is preferred to select and combine the preferred aspects and embodiments described herein, and specific objects resulting from each combination of preferred embodiments also belong to the present disclosure.
[0032] Detailed Description of the Invention The present invention is based on the development of new expression vectors for antibody constructs. The different polypeptide chains of the antibody constructs are encoded on these vectors in a single open reading frame. Each polypeptide chain is connected within this open reading frame via a peptide linker containing a 2A peptide. The 2A peptide is a "self-cleaving" peptide that automatically generates separate polypeptide chains after translation. The open reading frames encoding the different polypeptide chains are transcribed into a single mRNA, which is then translated and automatically cleaved into the different polypeptide chains.
[0033] The amino acids of the 2A peptide linker remaining at the C-terminus of the N-terminal polypeptide chain can optionally be removed by incorporating a specific protease cleavage site between the N-terminal polypeptide chain and the 2A peptide and using a respective protease, such as furin. Advantageously, the N-terminal polypeptide chain is an antibody heavy chain. In this case, the remaining C-terminal amino acids of the linker peptide are removed when the natural C-terminal lysine residue of the heavy chain is cleaved by cellular carboxypeptidases.
[0034] To remove the remaining amino acids of the 2A peptide that remain at the N-terminus of the C-terminal polypeptide chain, the polypeptide chain can be encoded with a signal peptide that is cleaved by the cellular process of protein maturation, thereby removing the remaining amino acids of the 2A peptide.
[0035] The above approach is highly advantageous for producing antibody constructs, particularly those containing three or more different polypeptide chains. We have demonstrated that the use of separate expression constructs significantly increases balanced expression. Because different polypeptide chains are translated from the same mRNA, they are generally produced in equimolar amounts. This avoids the undesirable overproduction of some polypeptide chains due to unbalanced expression. Furthermore, when mRNA encoding several different polypeptide chains is translated using the 2A peptide technology, these polypeptide chains are produced in close proximity within the cell, likely because they are produced by the same ribosome. This significantly enhances correct chain pairing and protein assembly, increasing the relative amount of correctly formed antibody constructs and reducing undesired by-products, such as complexes with incorrect or missing polypeptide chains. This facilitates purification of the desired antibody construct and ultimately improves overall yield.
[0036] 1. Nucleic acid products encoding antibody constructs In view of these findings, in a first aspect, the present invention provides a nucleic acid product comprising one or more vector nucleic acids encoding an antibody construct comprising at least three different polypeptide chains, wherein the antibody construct comprises an antibody heavy chain, and at least two different polypeptide chains of the antibody construct are encoded within the same open reading frame, and consecutive polypeptide chains encoded within said open reading frame are connected by a peptide linker comprising a 2A peptide.
[0037] In particular, the nucleic acid product provides for more uniform cellular production of the polypeptide chains of the antibody construct compared to production of the polypeptide chains of the antibody construct using a nucleic acid product, in which each polypeptide chain of the antibody construct is encoded within a separate open reading frame.
[0038] The cellular production of polypeptide chains can be determined at the protein level or the mRNA level. More uniform cellular production of polypeptide chains refers, in particular, to a smaller difference in the amount of each polypeptide chain produced by the cell. In particular, the quotient of the maximum amount of polypeptide chains of an antibody construct produced by a host cell divided by the minimum amount of polypeptide chains is smaller when using a nucleic acid product according to the present invention, compared to a nucleic acid product in which each polypeptide chain of the antibody construct is encoded in a separate open reading frame. Furthermore, more uniform cellular production of polypeptide chains refers, for example, to a smaller difference in the amount of mRNA encoding each polypeptide chain produced by a cell. In particular, the quotient of the maximum amount of mRNA encoding the polypeptide chains of an antibody construct produced by a host cell divided by the minimum amount of mRNA encoding the polypeptide chains is smaller when using a nucleic acid product according to the present invention, compared to a nucleic acid product in which each polypeptide chain of the antibody construct is encoded in a separate open reading frame.
[0039] In particular embodiments, the amounts of different polypeptide chains of said antibody constructs in a cell do not differ by more than a factor of 20, in particular a factor of 10, 8, or 5. In further embodiments, the amounts of mRNA encoding different polypeptide chains of said antibody in a cell do not differ by more than a factor of 20, in particular a factor of 10, 8, or 5.
[0040] Furthermore, the nucleic acid product provides a higher relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody construct compared to the relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody construct using the nucleic acid product, particularly where each polypeptide chain of the antibody construct is encoded in a separate open reading frame. In certain embodiments, the relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody construct is at least 5 percentage points, particularly at least 10 percentage points, at least 15 percentage points, or at least 20 percentage points higher than the relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody construct using a nucleic acid product where each polypeptide chain is encoded in a separate open reading frame.
[0041] Comparisons with nucleic acid products in which each polypeptide chain is encoded in a separate open reading frame are particularly made using the same or very similar conditions and production means, particularly using the same coding sequence, the same promoter, the same host cell line, and under the same culture conditions.
[0042] 1.1 Nucleic acid products The nucleic acid product contains one or more open reading frames that together encode all of the polypeptide chains of the antibody construct. When the polypeptide chains of the antibody construct are encoded by multiple open reading frames, these open reading frames may be present on the same vector nucleic acid or on different vector nucleic acids. In certain embodiments, the nucleic acid product consists of one vector nucleic acid encoding the antibody construct. In these embodiments, one or more open reading frames encoding all of the polypeptide chains of the antibody construct are present on this vector nucleic acid. In other embodiments, the nucleic acid product consists of two or more, particularly two, vector nucleic acids encoding the antibody construct. In these embodiments, the polypeptide chains of the antibody construct are generally encoded by two or more open reading frames present on two or more vector nucleic acids. A single vector nucleic acid may contain one or more open reading frames encoding the polypeptide chains of the antibody construct. The use of only one vector nucleic acid is preferred.
[0043] Different polypeptide chains of an antibody construct that are encoded within the same open reading frame are connected by peptide linkers comprising 2A peptides. In embodiments in which more than two polypeptide chains of an antibody construct are encoded within the same open reading frame, peptide linkers comprising 2A peptides connect consecutive polypeptide chains.
[0044] In certain embodiments, the open reading frames encoding two or more polypeptide chains of the antibody construct are part of an expression cassette that allows the expression of the open reading frames. When the polypeptide chains of the antibody construct are encoded by multiple open reading frames, the different open reading frames can be part of the same expression cassette or separate expression cassettes. In embodiments where two or more open reading frames are part of the same expression cassette, the consecutive open reading frames are particularly connected by an internal ribosome entry site (IRES).
[0045] In particular, the expression cassette includes an open reading frame and a promoter operably linked to the open reading frame. The promoter used in the expression cassette can be any promoter suitable for driving expression in a mammalian host cell. For example, the promoter can be selected from the group consisting of a cytomegalovirus (CMV) promoter, a simian virus 40 (SV40) promoter, a ubiquitin C (UBC) promoter, an elongation factor 1 alpha (EF1A) promoter, a phosphoglycerate kinase (PGK) promoter, a Rous sarcoma virus (RSV) promoter, a BROAD3 promoter, a mouse rosa 26 promoter, a pCEFL promoter, and a β-actin promoter, optionally combined with a CMV early enhancer (CAGG). Specific examples of promoters include the cytomegalovirus immediate early promoter, the simian virus 40 early promoter, the human ubiquitin C promoter, the human elongation factor 1 alpha promoter, the mouse phosphoglycerate kinase 1 promoter, the Rous sarcoma virus long terminal repeat promoter, and the chicken β-actin promoter associated with the CMV early enhancer. In a specific embodiment, the promoter is a CMV promoter.
[0046] In embodiments in which the open reading frames encoding the polypeptide chains of an antibody construct are expressed by multiple expression cassettes, the expression cassettes preferably contain similar expression control elements, particularly promoters of similar strength. Different promoters or the same promoter can be used, particularly different promoters of similar strength.
[0047] The vector nucleic acid may contain additional elements such as a marker gene and an origin or replication. In some embodiments, the vector nucleic acid is suitable for stable transfection of a host cell, particularly a mammalian host cell such as a rodent or human cell, particularly a CHO cell. In particular, the vector nucleic acid is a plasmid.
[0048] In some embodiments, each vector nucleic acid of the nucleic acid product comprises at least one selectable marker gene, particularly a mammalian selectable marker gene, which allows for the selection of mammalian host cells containing said gene and thus the vector nucleic acid.
[0049] Non-limiting examples of mammalian selectable marker genes include antibiotic resistance genes that confer resistance to, for example, G418; hygromycin (hyg or hph, commercially available from Life Technologies, Inc., Gaithesboro, Md.); neomycin (neo, commercially available from Life Technologies, Inc., Gaithesboro, Md.); zeocin (Sh Ble, commercially available from Pharmingen, San Diego, Calif.); puromycin (pac, puromycin-N-acetyltransferase, available from Clontech, Palo Alto, Calif.), ouabain (oua, available from Pharmingen), and blasticidin (available from Invitrogen). Further suitable selectable marker genes include folate receptor genes, such as the folate receptor alpha gene, or genes encoding fluorescent proteins, such as GFP and RFP. Respective mammalian selectable marker genes are well known and allow for the selection of mammalian cells containing the gene and, therefore, cells containing the vector. Systems using folate receptor genes are described in WO 2009 / 080759 and WO 2015 / 015419. As used herein, the term "gene" also refers to a natural or synthetic polynucleotide that encodes a functional variant of a selection marker that provides the intended resistance. Thus, truncated or mutated forms of wild-type genes or synthetic polynucleotides are also encompassed, as long as they provide the intended resistance.
[0050] In some embodiments, the mammalian selectable marker gene may be amplifiable, allowing for selection and gene amplification of vector-containing mammalian host cells. A non-limiting example of an amplifiable selectable mammalian marker gene is the dihydrofolate reductase (DHFR) gene. Other systems currently in use include the glutamine synthetase (gs) system and the histidinol-driven selection system, among others. These amplifiable markers are also selectable markers and can be used to select for cells that have acquired the vector nucleic acid. In amplifiable systems such as the DHFR system, recombinant protein expression can be increased by exposing the cells to certain agents that promote gene amplification, such as antifolates (e.g., methotrexate (MTX)) in the case of the DHFR system. A suitable inhibitor of GS that promotes gene amplification is methionine sulfoximine (MSX). Exposure to MSX also results in gene amplification.
[0051] In embodiments in which the nucleic acid product comprises two or more vector nucleic acids, the different vector nucleic acids may, inter alia, comprise different selectable marker genes.
[0052] The vector nucleic acid is particularly suitable for integration into the genome of a host cell. In some embodiments, the host cell is stably transfected with the vector nucleic acid. In certain embodiments, the vector nucleic acid further comprises a prokaryotic selectable marker gene. The prokaryotic selectable marker may, for example, provide resistance to antibiotics such as ampicillin, kanamycin, tetracycline, and / or chloramphenicol.
[0053] 1.2 Antibody constructs An antibody construct may be any protein comprising three or more different polypeptide chains, where at least one of these polypeptide chains is an antibody heavy chain. Thus, the different polypeptide chains of an antibody construct include at least one antibody heavy chain, hereinafter also referred to as the first heavy chain.
[0054] In certain embodiments, the antibody heavy chain is one of at least two different polypeptide chains of the antibody construct encoded within the same open reading frame. In particular, the antibody heavy chain is the N-terminal polypeptide chain encoded within the open reading frame of the nucleic acid product.
[0055] The remaining polypeptide chains may be any polypeptide chains as long as they can be assembled together to form an antibody construct. In certain embodiments, the additional polypeptide chains comprise at least one antibody light chain and / or at least one additional antibody heavy chain different from the first heavy chain. In certain embodiments, all of the polypeptide chains of the antibody construct are antibody heavy chains and, optionally, antibody light chains. Exemplary sets of different polypeptide chains of the antibody construct include two different antibody heavy chains and two different antibody light chains, two different antibody heavy chains and one antibody light chain, one antibody heavy chain and two different antibody light chains, and two different antibody heavy chains and three different antibody light chains.
[0056] In certain embodiments, the antibody construct comprises an antibody light chain linked to a first heavy chain. This antibody light chain is also referred to hereinafter as the first light chain. In certain embodiments, the first heavy chain and the first light chain are encoded in the same open reading frame. In these embodiments, the first antibody heavy chain is preferably the N-terminal polypeptide chain encoded in the open reading frame. In particular, the first light chain is a second polypeptide chain encoded in the open reading frame to which the first heavy chain is connected by a peptide linker comprising a 2A peptide. In these embodiments, the open reading frame preferably encodes first the first heavy chain, then the peptide linker, and then the first light chain in the translational direction, such that the peptide linker connects the C-terminus of the heavy chain to the N-terminus of the light chain.
[0057] In certain embodiments, the first heavy chain comprises a heavy chain variable region and the first light chain comprises a light chain variable region. In these embodiments, the heavy chain variable region and the light chain variable region may, in particular, form an antigen-binding region. The antigen-binding region may, in particular, specifically bind to an antigen.
[0058] In certain embodiments, the antibody construct comprises a second antibody heavy chain. In particular, the second heavy chain is different from the first heavy chain. Preferably, the first heavy chain and the second heavy chain are linked to each other in the antibody construct. In certain embodiments, the first heavy chain and the second heavy chain are linked to each other using knob-into-hole technology.
[0059] In embodiments in which the antibody construct comprises a second heavy chain, the second heavy chain can be encoded within the same open reading frame as the first heavy chain. The first heavy chain, linker peptide, and second heavy chain can be encoded consecutively in that order from 5' to 3'. If the open reading frame encodes an additional polypeptide chain, such as a first light chain, the additional polypeptide chain can be encoded, for example, between the first and second heavy chains or after the second heavy chain.
[0060] In alternative embodiments, the antibody construct comprises a second heavy chain, which is encoded in a second open reading frame different from the open reading frame encoding the first heavy chain. In these embodiments, one or more additional polypeptide chains of the antibody construct may be encoded in the second open reading frame. In this case, the N-terminal polypeptide chain encoded in the second open reading frame is preferably the second heavy chain connected to the additional polypeptide chain encoded in the second open reading frame by a peptide linker comprising a 2A peptide.
[0061] In embodiments in which the antibody construct comprises a second heavy chain, the first heavy chain and the second heavy chain are specifically linked to one another using knob-into-hole technology.
[0062] In certain embodiments, the antibody construct comprises a second antibody light chain. In embodiments in which the antibody construct comprises a second antibody heavy chain and a second antibody light chain, the second light chain specifically binds to the second heavy chain. In these embodiments, the second heavy chain and the second light chain are preferably encoded within the same open reading frame, with a peptide linker connecting the two polypeptide chains, the peptide linker comprising a 2A peptide. In particular, the open reading frame first encodes the second heavy chain, then the peptide linker, and then the second light chain, in the translational direction, such that the peptide linker connects the C-terminus of the heavy chain to the N-terminus of the light chain.
[0063] In certain embodiments, the second heavy chain comprises a heavy chain variable region and the second light chain comprises a light chain variable region. In these embodiments, the heavy chain variable region and the light chain variable region may, in particular, form an antigen-binding region. The antigen-binding region may, in particular, specifically bind to an antigen.
[0064] In embodiments in which the heavy and light chain variable regions of a first heavy and light chain form a first antigen-binding region and the heavy and light chain variable regions of a second heavy and light chain form a second antigen-binding region, the first antigen-binding region is capable of specifically binding, in particular, to a first antigen, and the second antigen-binding region is capable of specifically binding, in particular, to a second antigen.
[0065] 1.3 Antibody heavy chain The heavy chain of an antibody according to the invention, also referred to herein as "heavy chain" or "antibody heavy chain", is a polypeptide chain comprising at least a portion of the heavy chain constant region of an antibody, in particular at least one immunoglobulin domain of the heavy chain constant region (also referred to as heavy chain constant domain (CH)), such as the CH1 domain, CH2 domain and CH3 domain.
[0066] In preferred embodiments, the antibody heavy chain comprises a CH3 domain. In certain embodiments, the CH3 domain comprises a lysine residue at its C-terminus.
[0067] As used herein, the term "CH3 domain" refers to an antibody heavy chain constant domain derived from the CH3 domain of a natural human antibody, particularly a natural human IgG antibody having a gamma heavy chain. Similarly, as used herein, the term "additional immunoglobulin domains" (VH, CH1, CH2, VL, CL) refers to an antibody heavy or light chain domain derived from the respective immunoglobulin domains of a natural human antibody, particularly a natural human IgG antibody having a gamma heavy chain and a kappa or lambda light chain. As used herein, the term "hinge region" refers to an antibody heavy chain hinge region derived from the hinge region of a natural human antibody, particularly a natural human IgG antibody having a gamma heavy chain. In this respect, the term "derived from" particularly means that the amino acid sequence of the immunoglobulin domain is at least 90% identical, particularly at least 95% identical, to the respective immunoglobulin domain of a natural human antibody. The immunoglobulin domains and hinge regions of an antibody, such as the VH, CH1, CH2, CH3, VL, CL, and hinge regions, are collectively referred to herein as antibody domains.
[0068] In certain embodiments, the antibody heavy chain comprises a CH2 domain, particularly a CH2 domain and a CH3 domain. In certain embodiments, the antibody heavy chain comprises a hinge region, a CH2 domain, and a CH3 domain. In particular, the antibody heavy chain can bind to another antibody heavy chain, and in particular can form a homodimer with the same antibody heavy chain or a heterodimer with another antibody heavy chain.
[0069] In certain embodiments, an antibody heavy chain contains one or more amino acid substitutions that make it suitable for knob-into-hole technology. According to this well-known technique, two different heavy chains are mutated to form a "knob" in one heavy chain and a corresponding "hole" in the other heavy chain. These knobs and holes are formed by introducing large, bulky amino acids as knobs and small amino acids as holes at positions of contact between the antibody. Suitable "knob" amino acids include, for example, tyrosine and tryptophan, and suitable "hole" amino acids include, for example, alanine, serine, threonine, and valine. The amino acid substitutions are generally located in the CH3 domain, since this domain provides the primary contact site between the two heavy chains of an antibody. Two or three "knobs" and a corresponding number of "holes" can also be used, where one heavy chain can contain both at least one knob and at least one hole. Knob-into-hole technology is well known and established in the art (see, e.g., Ridgway et al. (1996) Protein Engineering 9(7):617-621). Suitable mutations include T366W, T366Y, and T394W as knobs and T366S, L368A, F405A, Y407V, and Y407T as holes, with exemplary knob / hole pairs being T366Y / Y407T and F405A / T394W.
[0070] In certain embodiments, an antibody heavy chain comprises a CH1 domain and / or a heavy chain variable domain (VH). In particular, an antibody heavy chain comprises a CH1 domain and / or a VH domain in addition to a CH2 domain, a CH3 domain, and optionally a hinge region.
[0071] In particular, the antibody domains of the heavy chain, to the extent present, are arranged in the natural order as found in a native antibody, i.e., from N-terminus to C-terminus: VH domain, CH1 domain, hinge region, CH2 domain, and CH3 domain.
[0072] In certain embodiments, an antibody heavy chain comprises one or more additional polypeptide moieties in addition to the antibody domains. These additional polypeptide moieties can be located anywhere in the heavy chain, for example, at the N-terminus, C-terminus, or between two antibody domains. Specifically, the additional polypeptide moieties are positioned so as not to interfere with binding of the heavy chain to another heavy chain or to a light chain.
[0073] In certain embodiments, the antibody heavy chain is encoded by a signal peptide at the N-terminus. The signal peptide is a signal for the host cell to secrete the produced polypeptide chain and is cleaved after translation. In particular, the antibody heavy chain is encoded by a signal peptide when it is the first polypeptide chain encoded in an open reading frame.
[0074] In embodiments in which the antibody construct comprises at least two different antibody heavy chains, each of these heavy chains may independently possess one or more of the above characteristics. The different antibody heavy chains differ from each other in at least one amino acid.
[0075] 1.4 Antibody light chain The light chain of an antibody according to the invention, also referred to herein as "light chain" or "antibody light chain", is a polypeptide chain comprising at least a part of the heavy chain constant region of an antibody, in particular at least the immunoglobulin domain of the light chain constant region (also referred to as the light chain constant domain (CL)).
[0076] In a preferred embodiment, the antibody light chain comprises a CL domain, in particular a CL domain derived from a naturally occurring human antibody, in particular a naturally occurring human antibody having a kappa or lambda light chain.
[0077] In certain embodiments, the antibody light chain comprises a light chain variable domain (VL). In particular, the antibody light chain comprises a VL domain in addition to a CL domain. In particular, the antibody light chain can bind to an antibody heavy chain, and in particular can form a heterodimer with an antibody heavy chain.
[0078] In particular, the antibody domains of the light chain, to the extent present, are arranged in the natural order as found in naturally occurring antibodies, ie, from N-terminus to C-terminus of the VL and CL domains.
[0079] In embodiments in which an antibody construct comprises at least two different antibody light chains and at least two different antibody heavy chains, one or more amino acid residues at the interface between the heavy and light chains may be mutated in the antibody heavy and / or light chains to increase correct heavy-light chain pairing. In particular, one or both light chains and / or one or both heavy chains may be engineered to strongly favor each light chain for its cognate heavy chain. Respective techniques are known in the art. For example, the knob-into-hole technique described herein for pairing two heavy chains may be utilized. Alternatively or additionally, an electrostatic steering mechanism may be used, in which the charge distribution on the interaction surface between the light and heavy chains is engineered by amino acid substitutions such that repulsive electrostatic forces reduce or prevent binding of the light chain to the wrong heavy chain. In certain embodiments, the VH and CH1 domains of the heavy chain and the VL and CL domains of the light chain are engineered to improve correct chain pairing. In another embodiment, the VH and CH1 domains of the heavy chain and the VL and CL domains of the light chain are not engineered to improve correct chain pairing.
[0080] In certain embodiments, an antibody light chain comprises one or more additional polypeptide moieties in addition to the antibody domains. These additional polypeptide moieties can be located anywhere in the light chain, for example, at the N-terminus, C-terminus, or between the two antibody domains. Specifically, the additional polypeptide moieties are positioned so as not to interfere with binding of the light chain to the heavy chain.
[0081] In certain embodiments, the antibody light chain is encoded by a signal peptide at the N-terminus.
[0082] In embodiments in which the antibody construct comprises at least two different antibody light chains, each of these light chains may independently possess one or more of the above characteristics. The different antibody light chains differ from each other in at least one amino acid.
[0083] 1.5 Further Polypeptide Moieties The antibody heavy and light chains of the antibody construct may comprise further polypeptide moieties in addition to any antibody domains, which may be any polypeptide fused to the antibody domains.
[0084] The further polypeptide moiety has a specific function, such as binding to a target molecule. Examples of the further polypeptide moiety include single-chain antibody fragments, such as single-chain Fv fragments (scFv), consisting of a heavy-chain variable domain and a light-chain variable domain linked together by a peptide linker to form an antigen-binding site, and single-domain antibody fragments (sdAb), consisting of a heavy-chain variable domain derived from a heavy-chain antibody found in camelids. In particular, the further polypeptide moiety may provide an antigen-binding region. Further examples of polypeptide moieties include ligands, cytokines such as interleukins, cell adhesion molecules, growth factors, and functional fragments and constitutively active or dominant-negative mutants of these moieties. In certain embodiments, the further polypeptide moiety can bind to and / or activate or inhibit immune cells, such as T cells. The polypeptide moiety may also be a small peptide, such as a peptide toxin.
[0085] 1.6 Peptide Linker Polypeptide chains encoded within the same open reading frame are connected by peptide linkers containing 2A peptides, which connect the C-terminus of one polypeptide chain to the N-terminus of the next.
[0086] The 2A peptide in the peptide linker is a "self-cleaving" peptide. "Self-cleavage" occurs cotranslationally, resulting in an N-terminal polypeptide chain and a C-terminal polypeptide chain after translation. The underlying self-cleavage mechanism is not yet fully understood and may be based on, for example, cleavage of the peptide bond immediately after translation or skipping of the ribosome so that the peptide bond is not formed in the first place. In certain embodiments, the 2A peptide is derived from a virus selected from the group consisting of foot-and-mouth disease virus, equine rhinitis A virus, porcine teschovirus-1, and Thosea asigna virus. In further embodiments, the 2A peptide is derived from a non-viral organism, such as a sea urchin (e.g., Strongylocentrotus purpuratus), a sponge (e.g., Amphimedon queenslandica), a sea urchin (e.g., Saccoglossus kowalevskii), and an amphioxus (e.g., Branchiostoma floridae). In particular, the 2A peptide is derived from foot-and-mouth disease virus.
[0087] In certain embodiments, the 2A peptide has an amino acid sequence comprising the consensus sequence DXEXNPGP (SEQ ID NO: 8), in particular LXXXGDVEXNPGP (SEQ ID NO: 9). The 2A cleavage site is located between the C-terminal glycine and proline residues. The 2A peptide particularly comprises an amino acid sequence that is at least 80% identical over its entire length to one of the amino acid sequences according to SEQ ID NOs: 10-21, where in particular the consensus sequence of SEQ ID NO: 8, in particular the consensus sequence of SEQ ID NO: 9, is conserved. In certain embodiments, the 2A peptide comprises or consists of an amino acid sequence selected from SEQ ID NOs: 10-21, in particular the amino acid sequence of SEQ ID NO: 10, in particular the amino acid sequence of SEQ ID NO: 11.
[0088] In a preferred embodiment, the 2A peptide is located at the C-terminus of the linker peptide.Particularly, the C-terminal polypeptide chain is directly fused to the C-terminal proline residue of the cleavage site of the 2A peptide.Therefore, after the self-cleavage of the 2A peptide, the C-terminal polypeptide chain is formed with only the proline residue added at the N-terminus.
[0089] In certain embodiments, the peptide linker further comprises a protease recognition site at the N-terminus of the 2A peptide. In particular, the protease recognition site is a furin recognition site. The furin recognition site has, in particular, the amino acid sequence RX(R / K)R (SEQ ID NO: 22), in particular RKRR or RRKR (SEQ ID NOs: 23 and 24). In certain embodiments, the protease recognition site is located at the N-terminus of the linker peptide.
[0090] The protease recognition site may be fused directly to the 2A peptide, or an additional linker sequence may be present between the protease recognition site and the 2A peptide. The additional linker sequence may be any sequence, including a consensus linker sequence such as a GS linker, e.g., the amino acid sequence GSG, and a sequence derived from the source of the 2A peptide. In certain embodiments, the protease recognition site is fused directly to the 2A peptide, and the peptide linker consists of the protease recognition site and the 2A peptide.
[0091] In particular, the protease recognition site is a recognition site for a protease that is naturally expressed in the host cell used to produce the antibody construct. In particular, the protease is ubiquitously expressed in mammalian or even eukaryotic cells. Preferably, the protease is furin, which is expressed in almost all eukaryotic cells, particularly any mammalian cell used as a host cell in protein production. In other embodiments, a specific protease recognition site is used, and the host cell is engineered to express a protease that recognizes said protease recognition site, or a protease that recognizes said protease recognition site is added to the antibody construct during or after its production.
[0092] For example, the peptide linker may comprise or consist of an amino acid sequence according to SEQ ID NO:25.
[0093] The peptide linker may be of any length suitable for linking different polypeptide chains of the antibody construct and for containing the self-cleaving 2A peptide and optionally a protease recognition site, hi certain embodiments, the peptide linker has a length of 60 amino acids or less, particularly 50 amino acids or less, and more particularly 40 amino acids or less.
[0094] In embodiments in which the open reading frame of the nucleic acid product encodes multiple peptide linkers, each of these peptide linkers can independently have one or more of the above characteristics and can be different from one another or identical.
[0095] 1.7 Exemplary Nucleic Acid Products In one embodiment, the nucleic acid product comprises, in an N-terminal to C-terminal direction, within a first open reading frame (i) signal peptide; (ii) a first heavy chain comprising a first heavy chain variable region; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; and (v) a first light chain comprising a first light chain variable region; and, in the N-terminal to C-terminal direction, in a second open reading frame, (i) signal peptide; (ii) a second heavy chain comprising a second heavy chain variable region; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; and (v) a second light chain comprising a second light chain variable region; one or more vector nucleic acids encoding wherein the first heavy chain variable region and the first light chain variable region form an antigen-binding region capable of binding to a first antigen; the second heavy chain variable region and the second light chain variable region form an antigen-binding region capable of binding to a second antigen; and the first heavy chain and the second heavy chain are bound to each other using knob-into-hole technology.
[0096] In one embodiment, the nucleic acid products are arranged in the same open reading frame from N-terminal to C-terminal. (i) signal peptide; (ii) a first heavy chain comprising a first heavy chain variable region; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; (v) a first light chain comprising a first light chain variable region; (vi) a linker peptide comprising the 2A peptide; (vii) optionally, a signal peptide; (viii) a second heavy chain comprising a second heavy chain variable region; (ix) a linker peptide comprising a 2A peptide; (x) optionally a signal peptide; and (xi) a second light chain comprising a second light chain variable region; and one vector nucleic acid encoding wherein the first heavy chain variable region and the first light chain variable region form an antigen-binding region capable of binding to a first antigen; the second heavy chain variable region and the second light chain variable region form an antigen-binding region capable of binding to a second antigen; and the first heavy chain and the second heavy chain are bound to each other using knob-into-hole technology.
[0097] In one embodiment, the nucleic acid product comprises, in an N-terminal to C-terminal direction, within a first open reading frame (i) signal peptide; (ii) a first heavy chain comprising a heavy chain variable region; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; and (v) a light chain comprising a light chain variable region; and, in the N-terminal to C-terminal direction, in a second open reading frame, (i) a signal peptide; and (ii) a second heavy chain; one or more vector nucleic acids encoding wherein the heavy chain variable region and light chain variable region of the first heavy chain form an antigen-binding region capable of binding to a first antigen; the second heavy chain comprises an antigen-binding region capable of binding to a second antigen; and the first heavy chain and second heavy chain are bound to each other using knob-into-hole technology.
[0098] In one embodiment, the nucleic acid product comprises, in an N-terminal to C-terminal direction, within a first open reading frame (i) signal peptide; (ii) a first heavy chain; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; and (v) a second heavy chain; and, in the N-terminal to C-terminal direction, in a second open reading frame, (i) a signal peptide; and (v) a light chain comprising a light chain variable region; and one or more vector nucleic acids encoding (a) the first heavy chain comprises a heavy chain variable region that forms an antigen-binding region together with the light chain variable region that is capable of binding to a first antigen; and the second heavy chain comprises an antigen-binding region that is capable of binding to a second antigen; or (b) the first heavy chain comprises an antigen-binding region capable of binding to a first antigen; the second heavy chain comprises a heavy chain variable region that forms an antigen-binding region together with the light chain variable region, capable of binding to a second antigen; The first and second heavy chains are conjugated to each other using knob-into-hole technology.
[0099] In one embodiment, the nucleic acid product is located in an open reading frame from the N-terminus to the C-terminus. (i) signal peptide; (ii) a first heavy chain; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; (v) a second heavy chain comprising a heavy chain variable region; (vi) a linker peptide comprising the 2A peptide; (vii) optionally a signal peptide; and (viii) a light chain comprising a light chain variable region; and one vector nucleic acid encoding wherein the first heavy chain comprises an antigen-binding region capable of binding to a first antigen; the heavy chain variable region and light chain variable region of the second heavy chain form an antigen-binding region capable of binding to a second antigen; and the first heavy chain and second heavy chain are bound to each other using knob-into-hole technology.
[0100] 1.8 Further nucleic acid products In a further aspect, the present invention provides a nucleic acid product comprising one or more vector nucleic acids encoding an antibody construct comprising a first antibody heavy chain and a second antibody heavy chain different from the first antibody heavy chain, wherein at least two polypeptide chains of the antibody construct are encoded within the same open reading frame, and consecutive polypeptide chains within said open reading frame are connected by a peptide linker comprising a 2A peptide.
[0101] The features and embodiments disclosed above for the nucleic acid product according to the first aspect apply equally to this nucleic acid product. In certain embodiments, the nucleic acid product of this aspect consists of a single vector nucleic acid encoding an antibody construct consisting of a first and a second antibody heavy chain encoded in the same open reading frame connected to each other by a peptide linker comprising a 2A peptide.
[0102] 2.Host cells In a second aspect, the present invention provides a host cell comprising the nucleic acid product described herein.
[0103] The host cell may be any cell type, particularly a cell useful for recombinantly producing proteins. The host cell is particularly a cell capable of producing an antibody construct. In certain embodiments, the host cell is particularly a mammalian cell. The host cell may be, in particular, a rodent cell or a human cell. In certain embodiments, the mammalian cell is selected from the group consisting of, but not limited to, mouse cells such as COP, L, C127, Sp2 / 0, NS0, NS1, At20, and NIH3T3; rat cells such as PC12, PC12h, GH3, MtT, YB2 / 0, and YO; hamster cells such as BHK, CHO, and DHFR gene-deficient CHO; monkey cells such as COS1, COS3, COS7, CV1, and Vero; and human-derived cells such as Hela, HEK293, CAP, retina-derived PER-C6, diploid fibroblast-derived cells, myeloma cells, and HepG2. In certain embodiments, the host cell is a Chinese hamster ovary (CHO) cell. The host cells may be suitable for suspension and / or adherent culture, and may in particular be used in suspension culture.
[0104] In embodiments in which the peptide linker comprises a protease recognition site, the host cell expresses a protease that specifically recognizes and cleaves the protease recognition site. In particular, the peptide linker comprises a furin recognition site and the host cell expresses furin. The protease can be expressed inherently by the host cell, or the host cell can be engineered to express the protease. Preferably, the protease is expressed inherently by the host cell.
[0105] In a fifth aspect, the present invention provides a method for producing a host cell according to the present invention, comprising introducing a nucleic acid product described herein into a host cell. The nucleic acid product is artificially introduced into the host cell. In particular, the nucleic acid product is introduced by transfection. In this regard, transfection can be transient or stable, and in particular, stable transfection is used. Thus, in certain embodiments, the host cell comprises the nucleic acid product stably integrated into its genome.
[0106] The present invention further provides the use of the nucleic acid product for transfection of a host cell, in particular a mammalian cell such as a Chinese hamster ovary (CHO) cell.
[0107] 3. Production method In a third aspect, the present invention provides a method for producing a medicament for the treatment of a pulmonary arthritis, comprising: (a) providing a host cell according to the second aspect of the invention; (b) culturing the host cells in cell culture under conditions that allow the production of the antibody construct; (c) obtaining the antibody construct from the cell culture; and (d) Optionally, treating the antibody construct The present invention provides a method for producing an antibody construct, comprising:
[0108] In certain embodiments, the method further comprises, between steps (a) and (b): (a1) inoculating a cell culture medium with host cells to provide a cell culture; and (a2) culturing host cells in cell culture under conditions that allow for an increase in cell number in the cell culture; Further includes:
[0109] Appropriate conditions for culturing host cells, expanding their cell numbers, and expressing the antibody construct depend on the specific host cells, vectors, and expression cassettes used in the method. Those skilled in the art can easily determine appropriate conditions, which are already known in the art for multiple host cells. In certain embodiments, the nucleic acid product in the host cells contains one or more selectable marker genes. In these embodiments, the culture conditions in steps (a2) and / or (b) may include the presence of a corresponding selection agent in the cell culture medium.
[0110] Obtaining the antibody construct from the cell culture in step (c) particularly includes isolating the antibody construct from the cell culture. Isolation of the antibody construct particularly refers to separation of the antibody construct from the remaining components of the cell culture. As used herein, the term "cell culture" particularly includes cell culture medium and cells. In certain embodiments, the antibody construct is secreted by the host cells. In these embodiments, the antibody construct is isolated from the cell culture medium. Separation of the antibody construct from the cell culture medium can be performed, for example, by chromatographic methods. Suitable methods and means for isolating antibody constructs are known in the art and can be easily applied by those skilled in the art.
[0111] The obtained antibody construct may optionally be subjected to further processing steps, such as, for example, further purification, modification, and / or formulation steps to produce an antibody construct with the desired quality and composition. Such further processing steps and methods are generally known in the art. Suitable purification steps include, for example, affinity chromatography, size exclusion chromatography, anion and / or cation exchange chromatography, hydrophilic interaction chromatography, and reverse-phase chromatography. Further steps may include viral inactivation, ultrafiltration, and diafiltration. Formulation steps may include buffer exchange, addition of formulation components, pH adjustment, and concentration adjustment. Any combination of these and further steps may be used.
[0112] In certain embodiments, the method for producing an antibody construct further comprises, as step (d) or as part of step (d), providing a pharmaceutical formulation comprising the antibody construct. Providing a pharmaceutical formulation comprising the antibody construct or formulating the antibody construct as a pharmaceutical composition particularly comprises exchanging the buffer or buffer components of the composition comprising the antibody construct. Furthermore, this step may comprise lyophilizing the antibody construct. In particular, the antibody construct is transferred into a composition comprising only pharmaceutically acceptable ingredients.
[0113] In certain embodiments, the polypeptide chains of the antibody product are produced more uniformly compared to production of the polypeptide chains of the antibody construct using a nucleic acid product in which each polypeptide chain of the antibody construct is encoded in a separate open reading frame, and in certain embodiments, the relative amount of correctly assembled antibody construct is higher compared to production of the antibody construct using a nucleic acid product in which each polypeptide chain of the antibody construct is encoded in a separate open reading frame.
[0114] In a fourth aspect, the present invention further provides the use of a nucleic acid product as described herein or a host cell as described herein for the production of an antibody construct. The features and embodiments of the methods for producing an antibody construct as described herein apply equally to this use.
[0115] 4. Specific Embodiments The following describes specific embodiments of the present invention, which can be combined with additional embodiments, features, and examples described herein.
[0116] Embodiment 1. A nucleic acid product comprising one or more vector nucleic acids encoding an antibody construct comprising at least three distinct polypeptide chains, the antibody construct comprises an antibody heavy chain; at least two different polypeptide chains of the antibody construct are encoded within the same open reading frame; A nucleic acid product, wherein the continuous polypeptide chains encoded within the open reading frames are connected by peptide linkers comprising 2A peptides.
[0117] Embodiment 2. A nucleic acid product consisting of one or more vector nucleic acids encoding an antibody construct comprising a first antibody heavy chain and a second antibody heavy chain different from the first antibody heavy chain, wherein at least two polypeptide chains of the antibody construct are encoded within the same open reading frame, and wherein consecutive polypeptide chains within said open reading frame are connected by a peptide linker comprising a 2A peptide.
[0118] Embodiment 3. The nucleic acid product of embodiment 1 or 2, wherein the (first) antibody heavy chain is one of at least two different polypeptide chains of the antibody construct encoded within the same open reading frame.
[0119] Embodiment 4. The nucleic acid product of embodiment 3, wherein the N-terminal polypeptide chain encoded within said open reading frame is a (first) antibody heavy chain.
[0120] Embodiment 5. A nucleic acid product according to any one of embodiments 1 to 4, consisting of one vector nucleic acid encoding an antibody construct.
[0121] Embodiment 6. The nucleic acid product of any one of embodiments 1 to 5, wherein the antibody construct comprises an antibody light chain linked to a heavy chain.
[0122] Embodiment 7. The nucleic acid product of embodiment 6, wherein the at least two polypeptide chains encoded within the same open reading frame comprise a heavy chain and a light chain.
[0123] Embodiment 8. The nucleic acid product of embodiment 7, wherein the light chain is the second polypeptide chain encoded within the open reading frame.
[0124] Embodiment 9. The nucleic acid product of embodiment 8, wherein a peptide linker connects the C-terminus of the heavy chain to the N-terminus of the light chain.
[0125] Embodiment 10. The nucleic acid product of any one of embodiments 6 to 9, wherein the heavy chain comprises a heavy chain variable region, the light chain comprises a light chain variable region, and the heavy chain variable region and the light chain variable region form an antigen-binding region.
[0126] Embodiment 11. The nucleic acid product of any one of embodiments 1 to 10, wherein the antibody construct comprises a second antibody heavy chain.
[0127] Embodiment 12. The nucleic acid product of embodiment 11, wherein the first heavy strand and the second heavy strand are linked to each other using knob-into-hole technology.
[0128] Embodiment 13. The nucleic acid product of embodiment 11 or 12, wherein the at least two polypeptide chains encoded within the same open reading frame comprise a first heavy chain and a second heavy chain.
[0129] Embodiment 14. The nucleic acid product of embodiment 11 or 12, wherein the second heavy chain is encoded in a second open reading frame that is distinct from the first open reading frame encoding the first heavy chain.
[0130] Embodiment 15. At least two different polypeptide chains of the antibody construct are encoded in a second open reading frame, 15. The nucleic acid product of embodiment 14, wherein the N-terminal polypeptide chain encoded in the second open reading frame is a second heavy chain connected to a further polypeptide chain encoded in the second open reading frame by a peptide linker comprising a 2A peptide.
[0131] Embodiment 16. The nucleic acid product of any one of embodiments 11 to 15, wherein the antibody construct comprises a second light chain that binds to a second heavy chain.
[0132] Embodiment 17. The nucleic acid product of embodiment 16, wherein the second heavy chain and the second light chain are encoded within the same open reading frame with a peptide linker connecting the two polypeptide chains, wherein the peptide linker comprises a 2A peptide.
[0133] Embodiment 18. The nucleic acid product of embodiment 17, wherein a peptide linker connects the C-terminus of the second heavy chain to the N-terminus of the second light chain.
[0134] Embodiment 19. The nucleic acid product of any one of embodiments 16 to 18, wherein the second heavy chain comprises a heavy chain variable region, the second light chain comprises a light chain variable region, and the chain variable regions of the second heavy chain and the second light chain form an antigen-binding region.
[0135] Embodiment 20. The nucleic acid product according to any one of embodiments 1 to 19, wherein at least one heavy chain of the antibody construct, in particular each heavy chain, comprises at least one heavy chain constant domain (CH), in particular at least CH2 or CH3, in particular CH2 and CH3.
[0136] Embodiment 21. The nucleic acid product of any one of embodiments 1 to 20, wherein at least one heavy chain of the antibody construct, in particular each heavy chain, is capable of forming homodimers and / or heterodimers with another antibody heavy chain.
[0137] Embodiment 22. The nucleic acid product of any one of embodiments 1 to 21, wherein at least one heavy chain of the antibody construct, in particular each heavy chain, comprises a hinge region.
[0138] Embodiment 23. The nucleic acid product of any one of embodiments 1 to 22, wherein at least one heavy chain of the antibody construct, in particular each heavy chain, comprises a CH1 domain.
[0139] Embodiment 24. The nucleic acid product of any one of embodiments 1 to 23, wherein at least one heavy chain of the antibody construct, in particular each heavy chain, comprises a heavy chain variable domain (VH).
[0140] Embodiment 25. The nucleic acid product of any one of embodiments 1 to 24, wherein at least one heavy chain of the antibody construct, in particular each heavy chain, comprises one or more further polypeptide moieties.
[0141] Embodiment 26. The nucleic acid product of any one of embodiments 1 to 25, wherein at least one heavy chain of the antibody construct, in particular each heavy chain, comprises an antigen-binding region.
[0142] Embodiment 27. The nucleic acid product of any one of embodiments 1 to 26, wherein at least one light chain of the antibody construct, in particular each light chain, comprises a light chain constant domain (CL).
[0143] Embodiment 28. The nucleic acid product according to any one of embodiments 1 to 27, wherein at least one light chain of the antibody construct, in particular each light chain, is capable of forming a heterodimer with an antibody heavy chain.
[0144] Embodiment 29. The nucleic acid product of any one of embodiments 1 to 28, wherein at least one light chain of the antibody construct, in particular each light chain, comprises a light chain variable domain (VL).
[0145] Embodiment 30. The nucleic acid product of any one of embodiments 1 to 29, wherein at least one light chain of the antibody construct, in particular each light chain, comprises one or more further polypeptide moieties.
[0146] Embodiment 31. The nucleic acid product of any one of embodiments 1 to 30, wherein at least one light chain of the antibody construct, in particular each light chain, comprises an antigen-binding region.
[0147] Embodiment 32. The nucleic acid product of any one of embodiments 1 to 31, wherein the first heavy chain of the antibody construct is encoded by a signal peptide at the N-terminus.
[0148] Embodiment 33. The nucleic acid product of embodiment 32, wherein each heavy chain of the antibody construct is encoded by a signal peptide at the N-terminus.
[0149] Embodiment 34. The nucleic acid product of any one of embodiments 1 to 33, wherein the first light chain of the antibody construct is encoded by a signal peptide at the N-terminus.
[0150] Embodiment 35. The nucleic acid product of embodiment 34, wherein each light chain of the antibody construct is encoded by a signal peptide at the N-terminus.
[0151] Embodiment 36. One or more vector nucleic acids comprise, in an N-terminal to C-terminal direction, a first open reading frame (i) signal peptide; (ii) a first heavy chain comprising a first heavy chain variable region; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; and (v) a first light chain comprising a first light chain variable region; and one or more vector nucleic acids encode, in an N-terminal to C-terminal direction, (i) signal peptide; (ii) a second heavy chain comprising a second heavy chain variable region; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; and (v) a second light chain comprising a second light chain variable region; Code the first heavy chain variable region and the first light chain variable region form an antigen-binding region capable of binding to a first antigen; the second heavy chain variable region and the second light chain variable region form an antigen-binding region capable of binding to a second antigen; 36. The nucleic acid product of any one of embodiments 1 to 35, wherein the first heavy strand and the second heavy strand are linked to each other using knob-into-hole technology.
[0152] Embodiment 37. The vector nucleic acid is, in the N-terminal to C-terminal direction, in the same open reading frame (i) signal peptide; (ii) a first heavy chain comprising a first heavy chain variable region; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; (v) a first light chain comprising a first light chain variable region; (vi) a linker peptide comprising the 2A peptide; (vii) optionally, a signal peptide; (viii) a second heavy chain comprising a second heavy chain variable region; (ix) a linker peptide comprising a 2A peptide; (x) optionally a signal peptide; and (xi) a second light chain comprising a second light chain variable region; Code the first heavy chain variable region and the first light chain variable region form an antigen-binding region capable of binding to a first antigen; the second heavy chain variable region and the second light chain variable region form an antigen-binding region capable of binding to a second antigen; 36. The nucleic acid product of any one of embodiments 1 to 35, wherein the first heavy strand and the second heavy strand are linked to each other using knob-into-hole technology.
[0153] Embodiment 38. One or more vector nucleic acids comprise, in an N-terminal to C-terminal direction, a first open reading frame (i) signal peptide; (ii) a first heavy chain comprising a heavy chain variable region; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; and (v) a light chain comprising a light chain variable region; and one or more vector nucleic acids encode, in an N-terminal to C-terminal direction, (i) a signal peptide; and (ii) a second heavy chain; Code the heavy chain variable region and light chain variable region of the first heavy chain form an antigen-binding region capable of binding to a first antigen; the second heavy chain comprises an antigen-binding region capable of binding to a second antigen; 36. The nucleic acid product of any one of embodiments 1 to 35, wherein the first heavy strand and the second heavy strand are linked to each other using knob-into-hole technology.
[0154] Embodiment 39. One or more vector nucleic acids comprise, in an N-terminal to C-terminal direction, a first open reading frame (i) signal peptide; (ii) a first heavy chain; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; and (v) a second heavy chain; and one or more vector nucleic acids encode, in an N-terminal to C-terminal direction, (i) a signal peptide; and (v) a light chain comprising a light chain variable region; Code (a) the first heavy chain comprises a heavy chain variable region that forms an antigen-binding region together with the light chain variable region that is capable of binding to a first antigen; and the second heavy chain comprises an antigen-binding region that is capable of binding to a second antigen; or (b) the first heavy chain comprises an antigen-binding region capable of binding to a first antigen; the second heavy chain comprises a heavy chain variable region that forms an antigen-binding region together with the light chain variable region, capable of binding to a second antigen; 36. The nucleic acid product of any one of embodiments 1 to 35, wherein the first heavy strand and the second heavy strand are linked to each other using knob-into-hole technology.
[0155] Embodiment 40. The vector nucleic acid is, in an N-terminal to C-terminal direction, in an open reading frame (i) signal peptide; (ii) a first heavy chain; (iii) a linker peptide containing the 2A peptide; (iv) optionally, a signal peptide; (v) a second heavy chain comprising a heavy chain variable region; (vi) a linker peptide comprising the 2A peptide; (vii) optionally a signal peptide; and (viii) a light chain comprising a light chain variable region; Code the first heavy chain comprises an antigen-binding region capable of binding to a first antigen; the heavy chain variable region and light chain variable region of the second heavy chain form an antigen-binding region capable of binding to a second antigen; 36. The nucleic acid product of any one of embodiments 1 to 35, wherein the first heavy strand and the second heavy strand are linked to each other using knob-into-hole technology.
[0156] Embodiment 41. The nucleic acid product of any one of embodiments 1 to 40, wherein the 2A peptide is derived from a virus selected from the group consisting of foot-and-mouth disease virus, equine rhinitis A virus, porcine teschovirus-1, and Thosea asigna virus.
[0157] Embodiment 42. The nucleic acid product of any one of embodiments 1 to 41, wherein the peptide linker further comprises a protease recognition site at the N-terminus of the 2A peptide.
[0158] Embodiment 43. The nucleic acid product of embodiment 42, wherein the protease recognition site is a furin recognition site.
[0159] Embodiment 44. The nucleic acid product of any one of embodiments 1 to 43, wherein the peptide linker comprises an amino acid sequence according to SEQ ID NO: 25.
[0160] Embodiment 45. The nucleic acid product of any one of embodiments 1 to 44, which provides for more uniform cellular production of the polypeptide chains of the antibody construct compared to production of the polypeptide chains of the antibody construct using a nucleic acid product in which each polypeptide chain of the antibody construct is encoded within a separate open reading frame.
[0161] Embodiment 46. The nucleic acid product of embodiment 45, wherein the amounts of mRNA encoding the different polypeptide chains of said antibody constructs in a cell do not differ by more than a factor of 20.
[0162] Embodiment 47. The nucleic acid product of embodiment 45, wherein the amounts of mRNA encoding the different polypeptide chains of said antibody constructs in a cell do not differ by more than a factor of 10.
[0163] Embodiment 48. The nucleic acid product of embodiment 45, wherein the amounts of mRNA encoding the different polypeptide chains of said antibody constructs in a cell do not differ by more than a factor of 8.
[0164] Embodiment 49. The nucleic acid product of embodiment 45, wherein the amounts of mRNA encoding the different polypeptide chains of said antibody constructs in a cell do not differ by more than a factor of 5.
[0165] Embodiment 50. The nucleic acid product of any one of embodiments 1 to 49, wherein each polypeptide chain of the antibody construct is encoded in a separate open reading frame, and wherein the nucleic acid product provides a higher relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody construct compared to the relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody construct using the nucleic acid product.
[0166] Embodiment 51. The nucleic acid product of embodiment 50, wherein the relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody constructs is at least 5 percentage points higher than the relative amount of correctly assembled antibody constructs using the nucleic acid product, wherein each polypeptide chain is encoded in a separate open reading frame.
[0167] Embodiment 52. The nucleic acid product of embodiment 50, wherein the relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody constructs is at least 10 percentage points higher than the relative amount of correctly assembled antibody constructs using the nucleic acid product, wherein each polypeptide chain is encoded in a separate open reading frame.
[0168] Embodiment 53. The nucleic acid product of embodiment 50, wherein the relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody constructs is at least 15 percentage points higher than the relative amount of correctly assembled antibody constructs using the nucleic acid product, wherein each polypeptide chain is encoded in a separate open reading frame.
[0169] Embodiment 54. The nucleic acid product of embodiment 50, wherein the relative amount of correctly assembled antibody constructs after expression of the polypeptide chains of the antibody constructs is at least 20 percentage points higher than the relative amount of correctly assembled antibody constructs using the nucleic acid product, wherein each polypeptide chain is encoded in a separate open reading frame.
[0170] Embodiment 55. The nucleic acid product of any one of embodiments 1 to 54, wherein the open reading frames encoding two or more polypeptide chains of the antibody construct are part of an expression cassette allowing expression of the open reading frames.
[0171] Embodiment 56. The nucleic acid product of any one of embodiments 1 to 55, wherein the vector nucleic acid is a plasmid.
[0172] Embodiment 57. A host cell comprising a nucleic acid product according to any one of embodiments 1 to 56.
[0173] Embodiment 58. A host cell according to embodiment 57, which is a mammalian cell, in particular a human or rodent cell, such as a CHO cell.
[0174] Embodiment 59. (a) providing a host cell according to embodiment 57 or 58; (b) culturing the host cells in cell culture under conditions that allow the production of the antibody construct; (c) obtaining the antibody construct from the cell culture; and (d) Optionally, treating the antibody construct A method for producing an antibody construct, comprising:
[0175] Embodiment 60. The method of embodiment 59, wherein step (c) comprises isolating the antibody construct and / or separating the antibody construct from the remaining components of the cell culture.
[0176] Embodiment 61. The method of embodiment 59 or 60, wherein step (d) comprises formulating the antibody construct as a pharmaceutical composition.
[0177] Embodiment 62. The method of any one of embodiments 59 to 61, wherein the polypeptide chains of the antibody product are produced more uniformly compared to producing the polypeptide chains of the antibody construct using a nucleic acid product in which each polypeptide chain of the antibody construct is encoded within a separate open reading frame.
[0178] Embodiment 63 The method of embodiment 62, wherein the amounts of mRNA encoding the different polypeptide chains of said antibody constructs in the cell do not differ by more than a factor of 20.
[0179] Embodiment 64 The method of embodiment 62, wherein the amounts of mRNA encoding the different polypeptide chains of said antibody constructs in the cell do not differ by more than a factor of 10.
[0180] Embodiment 65. The method of embodiment 62, wherein the amounts of mRNA encoding the different polypeptide chains of said antibody constructs in the cell do not differ by more than a factor of 8.
[0181] Embodiment 66 The method of embodiment 62, wherein the amounts of mRNA encoding the different polypeptide chains of said antibody constructs in the cell do not differ by more than a factor of 5.
[0182] Embodiment 67. The method of any one of embodiments 51 to 54, wherein the relative amount of correctly assembled antibody construct is higher compared to production of antibody constructs using nucleic acid products in which each polypeptide chain of the antibody construct is encoded within a separate open reading frame.
[0183] Embodiment 68. The method of embodiment 67, wherein the relative amount of correctly assembled antibody constructs is at least 5 percentage points higher than the relative amount of correctly assembled antibody constructs using nucleic acid products in which each polypeptide chain is encoded in a separate open reading frame.
[0184] Embodiment 69. The method of embodiment 67, wherein the relative amount of correctly assembled antibody constructs is at least 10 percentage points higher than the relative amount of correctly assembled antibody constructs using nucleic acid products in which each polypeptide chain is encoded in a separate open reading frame.
[0185] Embodiment 70. The method of embodiment 67, wherein the relative amount of correctly assembled antibody constructs is at least 15 percentage points higher than the relative amount of correctly assembled antibody constructs using nucleic acid products in which each polypeptide chain is encoded in a separate open reading frame.
[0186] Embodiment 71. The method of embodiment 67, wherein the relative amount of correctly assembled antibody constructs is at least 20 percentage points higher than the relative amount of correctly assembled antibody constructs using nucleic acid products in which each polypeptide chain is encoded in a separate open reading frame.
[0187] Embodiment 72. Use of a nucleic acid product according to any one of embodiments 1 to 56 or a host cell according to embodiment 57 or 58 for the production of an antibody construct.
[0188] Embodiment 73. A method for producing a host cell according to embodiment 57 or 58, comprising introducing a nucleic acid product according to any one of embodiments 1 to 56 into a host cell. [Brief explanation of the drawings]
[0189] [Figure 1]The principle of a standard two-vector setup for the expression of bispecific antibody constructs (bsAbs) and the construction of bsAbs using knob-into-hole (KiH) technology are shown. [Figure 2] The principle cellular mechanism that occurs when using the 2A / furin linker peptide in a vector setup containing two plasmids and two mRNAs, combining the two chains in one expression cassette, is shown. [Figure 3] An overview of the molecular structure and the standard and 2A / furin vector configurations tested for the expression of bispecific antibodies is shown. [Figure 4] The relative mRNA levels of heavy and light chains using the different vector configurations shown in FIG. 3 are shown. [Figure 5] Figure 4 shows pooled productivity of bispecific antibodies using different vector configurations shown in Figure 3. [Figure 6] 2A / furin vector configurations tested for expression of bispecific antibodies are shown. [Figure 7] The relative mRNA levels of heavy and light chains using the different vector configurations shown in FIG. 6 are shown. [Figure 8] Figure 7 shows pooled productivity of bispecific antibodies using different vector configurations as shown in Figure 6. [Figure 9] Standard (B) and furin / 2A (C) vector configurations of the trifunctional antibody construct (A) are shown. [Figure 10] Pool productivity and quality analysis by SEC and labchip of trifunctional antibody constructs using standard (A) and furin / 2A (B) vector configurations shown in Figure 9. Antibody titers and percentages of main peaks obtained by SEC and labchip analysis, respectively, are shown. DETAILED DESCRIPTION OF THE INVENTION
[0190] Example Example 1: Standard vector design and vector design according to the invention. Compared to monoclonal antibodies, the complexity of developing cell lines expressing correctly assembled bispecific antibody constructs (bsAbs) is increased by the need to express four chains. Cotransfection and simultaneous selection of two separate plasmids, each expressing one of two light chains (LC) and one of two heavy chains (HC) in a separate expression cassette, can result in heterogeneous pools of cells that have integrated no plasmids, one or two plasmids, or unequal numbers of the two. Furthermore, different transcription and translation efficiencies of individual chains can lead to imbalances in mRNA and protein levels of individual chains. Uneven distribution of protein chains can prevent correct protein assembly, and close proximity of individual chains can result in undesired species, such as mismatched antibody constructs, partially assembled bispecific antibodies, and homodimers, complicating the purification process. The standard vector setup and production process are shown in Figure 1.
[0191] In the newly developed vector configuration, the heavy and light chains of one arm of a bispecific antibody are encoded in a single open reading frame, separated by a linker peptide containing a furin recognition site and a 2A peptide. Transcription generates one mRNA encoding chain 1-2AF-chain 2 (HC1-knob-furin / 2A linker-LC1) from one plasmid, and another mRNA encoding chain 3-2AF-chain 4 (HC2-hole-furin / 2A linker-LC2) from the second plasmid (see Figure 2). Cleavage of the 2A peptide (1) results in two distinct proteins after translation of the 2A peptide. Cotranslation of the corresponding light and heavy chains from a single mRNA favors correct chain pairing and protein assembly. Furin (2) cleaves the remaining amino acids of the N-terminal 2A peptide in the Golgi apparatus. Carboxypeptidase D (3) cleaves the C-terminal lysine and remaining furin cleavage site of the heavy chain, and signal peptide peptidase (4) cleaves the remaining C-terminal proline of the 2A peptide together with the signal peptide of the light chain.
[0192] The vector design of the present invention is superior, as shown in the following examples: 1) Combining expression of individual chains from one mRNA results in balanced mRNA and protein levels, overcoming expression imbalances. 2) Pool productivity is comparable. 3) The percentage of correctly paired bispecific antibody constructs is increased when LC1 and HC1 are encoded by one single mRNA and LC2 and HC2 are encoded by a second single mRNA, and when all four chains are encoded by one single mRNA. 4) When the two proteins are expressed in the order HC-furin / 2A-LC, the N- and C-termini of the heavy and light chains are processed correctly. When the furin / 2A peptide is at the C-terminus of the light chain, different amino acid extensions remaining from the furin recognition site were observed (R, RK, and RKR). 5) The rate of mismatched species in bispecific antibody constructs produced by knob-into-hole (KiH) technology is reduced.
[0193] Example 2: Comparison of standard and different furin / 2A vector designs. A single vector can encode several strands, allowing transfection and selection of one plasmid instead of co-transfection of two separate plasmids. Transfection and selection of a single plasmid increases the likelihood of obtaining a more homogeneous pool, i.e., cells either integrating the plasmid or not. Co-transfection and co-selection can result in a more heterogeneous pool, i.e., cells integrating no plasmid, one or two plasmids, or unequal numbers of the two plasmids.
[0194] Four different furin / 2A vector designs were compared with a standard vector design. In the standard design, each of the four distinct polypeptide chains of the bispecific antibody construct is encoded in a separate open reading frame, resulting in four distinct mRNAs. The expression cassettes for the heavy and light chain pairs for each arm of the bispecific antibody reside on a single plasmid, such that host cells are transfected with two plasmids ("2 plasmids, 4 mRNAs"; see Figure 3, "STD").
[0195] In two of the four furin / 2A vector designs, each heavy and light chain pair was encoded within a single open reading frame, encoding first the heavy chain, then the furin / 2A linker, and then the light chain. These two open reading frames were on separate plasmids ("two plasmids, two mRNAs") or the same plasmid ("one plasmid, two mRNAs"). In the other two furin / 2A vector designs, all polypeptide chains of the bispecific antibody were encoded within the same open reading frame in the order HC1-furin / 2A-LC1-furin / 2A-HC2-furin / 2A-LC2 ("one plasmid, one mRNA"; see Figure 3, "2A / furin"). In the two different configurations, the coding regions for the two arms of the bispecific antibody were switched.
[0196] For bispecific antibody production, each plasmid was introduced into CHO cells. mRNA expression and production of correctly assembled and misassembled bispecific antibody constructs were measured.
[0197] The results in Figure 4 show that with the standard vector configuration, the mRNA levels of the different polypeptide chains were highly unbalanced. The "two-plasmid, two-mRNA configuration" improved the balance, and the one-plasmid configuration showed even more balanced mRNA levels. The one-plasmid configuration also significantly improved productivity (see Figure 5). In a one-plasmid, one-mRNA vector design, the order in which the different arms of the bispecific antibody are encoded within the open reading frame can affect productivity.
[0198] The correct assembly of bispecific antibody constructs, as well as the formation of mismatched constructs, homodimers, and half antibodies, is summarized in Table 1.
[0199] [Table 1]
[0200] Table 1 shows mass spectrometry data for Protein A capture material of the standard vector design ("STD") and different furin / 2A vector configurations ("2AF"). The percentage of correctly assembled bispecific antibodies increased with all furin / 2A vector configurations compared to the standard vector configuration. The highest percentage of correctly assembled bispecific antibodies was detected with the furin / 2A vector configuration encoding all four chains on a single mRNA and vector. However, light chain extensions with a furin / 2A peptide at the C-terminus were observed.
[0201] Example 3: Evaluation of the production of bispecific antibody constructs using various furin / 2A vector configurations with two mRNAs on one plasmid. Bispecific antibody constructs were produced using different designs: a standard vector configuration and a "one plasmid, two mRNA" furin / 2A vector configuration. Each arm of the bispecific antibody was encoded in a single open reading frame, with the heavy chain at the N-terminus, followed by the furin / 2A linker peptide and the light chain. Two furin / 2A vector configurations were designed, one in which the open reading frame encoding the first arm was located 5' of the open reading frame encoding the second arm, and one in which the order was reversed.
[0202] The mRNA levels of the different polypeptide chains were highly unbalanced in some standard vector configurations (see Figure 7, "STD 2 Plasmid 4 mRNA"). In contrast, in the furin / 2A vector configuration, the mRNA levels were well balanced. The productivity of all vector configurations was comparable (see Figure 8).
[0203] The correct assembly of bispecific antibody constructs, as well as the formation of mismatched constructs, homodimers, and half antibodies, is summarized in Table 2.
[0204] [Table 2]
[0205] Table 2 shows mass spectrometry data for Protein A capture material comparing different standard vector configurations ("STD") and the furin / 2A vector configuration ("2AF"). Expression of the furin / 2AF "one plasmid, two mRNA" vector configuration increased the percentage of correctly assembled bispecific antibodies and reduced the percentage of mismatched species for the candidates tested. The results also indicate that correct light chain pairing is achieved with the furin / 2A vector configuration, as the standard configuration produced over 30% mismatched light chains, compared to 10% for these configurations. This is presumably because the heavy-light chain pairs are encoded by the same mRNA and are therefore produced in close proximity within the cell.
[0206] A low rate of mismatches reduces the effort required for the purification process and minimizes the possibility of completely exchanged light chain species that cannot be removed by the purification process.
[0207] Example 4: Evaluation of the production of alternative antibody constructs using different furin / 2A vector configurations. Non-standard antibody constructs were also tested for expression in the new furin / 2A vector configuration. The exemplary antibody construct contains one arm with heavy and light chains forming a normal antigen-binding region specific for a first antigen (anti1), where an scFv fragment against a second antigen (anti2) is fused between the CH1 and hinge region of the heavy chain. The second arm is a heavy chain constant region containing the hinge, CH2, and CH3 domains, attached to the first arm using knob-into-hole technology, with a cell adhesion molecule fused to the N-terminus of the hinge region (see Figure 9A). Two of these constructs were designed with different knob and hole mutations in the CH3 domain (antibody construct AC3: arm1-knob / arm2-hole, and antibody construct AC4: arm1-hole / arm2-knob).
[0208] Following standard vector configuration, one plasmid containing the light and heavy chain expression cassettes for the first arm and one plasmid containing the expression cassette for the second arm were used (see Figure 9B). For the furin / 2A vector configuration, only one plasmid with one expression cassette or two expression cassettes was used. In designs with only one open reading frame, the coding regions were ordered 5' to 3' as HC2-furin / 2A-HC1-furin / 2A-LC1. In designs with two open reading frames, the furin / 2A linker was either between HC2 and HC1 or between HC1 and LC1 (see Figure 9C).
[0209] The plasmids were transfected into different CHO cell lines to produce antibody constructs under standard conditions. For the standard vector configuration, the two plasmids were transfected at a 1:1 ratio and a 1:2 ratio. The pool productivity for the standard vector configuration ranged from 0.5 to 0.75 g / L for both candidates, depending on the ratio of plasmids used during transfection and the host cell line used. The quality was analyzed by SEC and labchip, and the percentage of the main peak is shown (see Figure 10A).
[0210] Figure 10B shows increased pool productivity with the furin / 2A vector configuration compared to pools generated with the standard approach. Quality was analyzed by SEC and LabChip. The percentage of the major peak increased to 79% (SEC) and 87% (LabChip) with the first knob-into-hole design and up to 79% (SEC) and 89% (LabChip) with the second knob-into-hole design using the furin / 2A vector configuration compared to the standard approach.
[0211] These data demonstrate improved productivity and correct assembly of antibody constructs using the furin / 2A vector design.
[0212] Example 5: Materials and Methods. In Examples 1 to 4, the following materials and methods were used.
[0213] 1. Expression Vector Construction The vectors used in the examples consist of the following elements: hCMV promoter / enhancer driving expression of the individual genes required for assembly of the antibody construct, a polyadenylation signal (polyA), a folate receptor and DHFR gene as a selection marker, an Escherichia coli (E. coli) origin of replication (CoIE ori), and a beta-lactamase gene for ampicillin (amp) resistance to allow amplification in bacteria. Different plasmid configurations were evaluated and further details are provided in the figures.
[0214] 2. Cell Lines, Culture, Transfection, and Selection Two different parental CHO cell lines were used as host cell lines for the production of antibody constructs. The host cell lines were derived from the CHO-K1 cell line. A single vial from each CHO line was used to prepare the recombinant cell line. The CHO cell lines were suspended in a proprietary, chemically defined culture medium and cultured in shake flasks in a non-humidified shaking cabinet at 36.5°C, 150 rpm, and 10% CO2. Cell viability and growth rate were monitored by an automated system (ViCell, Beckman Coulter). Cells were passaged into fresh medium two to three times a week and maintained in logarithmic growth phase.
[0215] SwaI-linearized expression plasmids encoding antibody constructs were transfected by electroporation (Amaxa Nucleofection system, Lonza, Germany). Transfection reactions were carried out in chemically defined culture medium according to the manufacturer's instructions. Parental CHO cells used for transfection were in exponential growth phase with cell viability exceeding 95%. Transfections were performed at 5 × 10 per transfection. 6 Transfection was performed on 100 cells. Immediately after transfection, the cells were transferred to a shake flask containing chemically defined culture medium. The cell pool was incubated at 36.5°C, 10% CO for 48 hours before starting the selection process.
[0216] As described above, the selection procedure was carried out using the selectable markers encoded by the respective expression vectors. Both proteins (FolR and DHFR) are involved in the same molecular pathway: FolR transports folic acid and the folic acid analog MTX into cells, while DHFR converts folic acid into an important precursor for purine and methionine synthesis. Combining these selection principles allows for a specific and powerful selection strategy to enrich for recombinant cells expressing both recombinant proteins.
[0217] After 48 hours of transfection and growth under low folate conditions, additional selection pressure was applied by adding 10 nM MTX to the chemically defined culture medium. After pool harvest, cells were frozen in culture medium supplemented with 7.5% DMSO, and cell pellets were prepared.
[0218] 3. Gene Expression Analysis by Quantitative Real-time PCR RNA extraction was performed using the Qiagen RNeasy Mini Kit according to the manufacturer's instructions. For real-time qPCR, cDNA was synthesized from 200 ng / μl diluted RNA using High Capacity RNA-to-cDNA Master Mix (Applied Biosystems), and 10x diluted cDNA was analyzed in triplicate using the QuantiFast SYBR Green PCR Kit (Qiagen). GAPDH was amplified as an endogenous control for normalization. Amplification and analysis were performed using the ABIPRISM® 7900HT Sequence Detection System. For the calculation of relative quantity (RQ) of gene expression for sample comparisons, the comparison 2 -ΔΔCt The data were normalized using the method.
[0219] 4.Upstream processing Following selection, material was produced in either shake flask fed-batch cultures or tube spin bioreactors. Cells were inoculated into fed-batch cultures at a seeding density of 4E5 vc / ml (addition of the original feed solution began on day 3, and the culture temperature was changed to 33°C on day 5). In-process controls were performed to monitor the concentration of the antibody construct during cultivation. Individual cultures were cultivated for 14 days. At the end of the cultivation process, cells were separated from the culture supernatant by centrifugation followed by sterile filtration before further downstream processing. The volumetric productivity of the selected pool was measured by Protein A HPLC in the cell culture supernatant to determine all types of products bearing the Fc portion and related impurities.
[0220] 5. Capture by Affinity Liquid Chromatography with MabSelect™ SuRe™ Antibody constructs and potential antibody construct variants retaining the Fc portion were captured from the cell-free supernatant by an affinity liquid chromatography (ALC) step on MabSelect™ SuRe™.
[0221] Chromatography was performed at room temperature. Prior to loading, the column was equilibrated with 20 mM NaHPO / NaHPO, pH 7.0. To deplete the product (and product variants) of nonspecifically bound impurities, such as host cell proteins (HCPs), media components, and DNA, the chromatography column was washed with 250 mM arginine-HCl, 1 M NaCl, 88 mM NaOH, pH 9.0. The cell-free supernatant was then loaded onto the ALC column, which was then washed with the equilibration buffer. The antibody constructs and potential antibody construct variants were eluted from the chromatography column using 50 mM acetic acid, pH 3.0. The pH of the ALC eluate was adjusted to approximately pH 5.0 with 0.1 or 1 M Tris or 0.5 M Bis-Tris, respectively, before storage at 2–8 °C for analytical evaluation.
[0222] 6. Analytical Characterization and Purity Assessment The Protein A captured material from the pool was carefully evaluated by different analytical methods to determine product characteristics and quality parameters.
[0223] (a) LC-MS screening of intact antibody constructs and variants 100 μg of Protein A-purified antibody construct samples were lyophilized in a 96-well plate and dissolved in 100 μl of 50 nM Tris-HCl (pH 7.5) buffer. The samples were deglycosylated with PNGaseF (New England Biolabs) at 37°C for 18 hours. The samples were analyzed by LC-ESI-MS at 80°C using a MassPREP Micro Desalting Column 2 1 x 5 mm (Waters) on a UPLC (Waters) connected to a Vion Q-TOF mass spectrometer (Waters). A linear gradient was applied at 0.3 ml / min: Mobile Phase A: 0.1% formic acid in water; Mobile Phase B: 0.1% FA in acetonitrile: 0-2 min: 5% B, 2-12 min: 5-90% B. MS parameters were: ESI+ resolution mode, capillary voltage 3 kV, sampling cone voltage 40 V, source temperature 150°C, desolvation temperature 400°C. Data were processed by automated MaxEntl deconvolution using Genedata MS refiner software. Identification and relative quantification of antibody construct species and mismatched variants was based on theoretical mass agreement and the corresponding relative peak intensities in the deconvoluted mass spectrum.
[0224] (b) Labchip Non-reducing LabChip runs were performed using the Caliper Life Sciences HT Protein Express Reagent Kit and HT Protein Express LabChip according to the manufacturer's instructions. Protein A purified samples were prepared by adding 35 μL of IAM buffer (300 μL of 250 mM IAM in 3 mL of Protein Express sample buffer) to 5 μL of sample (1 mg / mL). The samples were heated at 70°C for 10 minutes, and then 70 μL of water was added before running the LabChip on the Caliper LifeSciences LabChip GXII.
[0225] (c) Size exclusion chromatography Protein A purified samples were loaded onto a Waters UPLC BEH200 (Waters #186005225, 1.7 μm, 4.6 mm × 150 mm) SEC column, pore size 200 Å. The mobile phase was 50 mM sodium phosphate solution, pH 6.0. The flow rate was 0-4 ml / min. The column temperature was 30°C. UV was recorded at 210 nm. Data acquisition and peak integration were performed using a Chromeleon™ 7 (Thermo Scientific).
[0226] [Table 3]
[0227] [Table 4]
Claims
1. A nucleic acid product comprising one or more vector nucleic acids encoding an antibody construct comprising at least three distinct polypeptide chains, One or more vector nucleic acids (a) in the first open reading frame, in the N-terminal to C-terminal direction, (i) a signal peptide; (ii) a first heavy chain comprising a first heavy chain variable region; (iii) a linker peptide comprising a 2A peptide; (iv) optionally a signal peptide; and (v) a first light chain comprising a first light chain variable region; and In the second open reading frame, in the N-terminal to C-terminal direction, (i) a signal peptide; (ii) a second heavy chain comprising a second heavy chain variable region; (iii) a linker peptide comprising a 2A peptide; (iv) optionally a signal peptide; and (v) a second light chain comprising a second light chain variable region; wherein the first heavy chain variable region and the first light chain variable region form an antigen-binding region capable of binding to a first antigen; the second heavy chain variable region and the second light chain variable region form an antigen-binding region capable of binding to a second antigen; the first heavy chain and the second heavy chain are bound to each other using knob-into-hole technology; or (b) in the same open reading frame, in the N-terminal to C-terminal direction: (i) a signal peptide; (ii) a first heavy chain comprising a first heavy chain variable region; (iii) a linker peptide comprising a 2A peptide; (iv) optionally a signal peptide; (v) a first light chain comprising a first light chain variable region; (vi) a linker peptide comprising a 2A peptide; (vii) optionally a signal peptide; (viii) a second heavy chain comprising a second heavy chain variable region; (ix) a linker peptide comprising a 2A peptide; (x) optionally a signal peptide; and (xi) a second light chain comprising a second light chain variable region; wherein the first heavy chain variable region and the first light chain variable region form an antigen-binding region capable of binding to a first antigen; the second heavy chain variable region and the second light chain variable region form an antigen-binding region capable of binding to a second antigen; the first heavy chain and the second heavy chain are bound to each other using knob-into-hole technology; or (c) in the first open reading frame, in the N-terminal to C-terminal direction, (i) a signal peptide; (ii) a first heavy chain comprising a heavy chain variable region; (iii) a linker peptide comprising a 2A peptide; (iv) optionally a signal peptide; and (v) a light chain comprising a light chain variable region; wherein the one or more vector nucleic acids encode, in an N-terminal to C-terminal direction, (i) a signal peptide; and (ii) a second heavy chain; wherein the heavy chain variable region and the light chain variable region of the first heavy chain form an antigen-binding region capable of binding to a first antigen; the second heavy chain comprises an antigen-binding region capable of binding to a second antigen; the first heavy chain and the second heavy chain are bound to each other using knob-into-hole technology; or (d) in the first open reading frame, in the N-terminal to C-terminal direction, (i) a signal peptide; (ii) a first heavy chain; (iii) a linker peptide comprising a 2A peptide; (iv) optionally a signal peptide; and (v) a second heavy chain; wherein the one or more vector nucleic acids encode, in an N-terminal to C-terminal direction, (i) a signal peptide; and (v) a light chain comprising a light chain variable region; wherein the first heavy chain comprises a heavy chain variable region that forms an antigen-binding region together with the light chain variable region that is capable of binding to a first antigen; the second heavy chain comprises an antigen-binding region that is capable of binding to a second antigen, or the first heavy chain comprises an antigen-binding region that is capable of binding to a first antigen; and the second heavy chain comprises a heavy chain variable region that forms an antigen-binding region together with the light chain variable region that is capable of binding to a second antigen; the first heavy chain and the second heavy chain are bound to each other using knob-into-hole technology; or (e) in the N-terminal to C-terminal direction, within the open reading frame: (i) a signal peptide; (ii) a first heavy chain; (iii) a linker peptide comprising a 2A peptide; (iv) optionally a signal peptide; (v) a second heavy chain comprising a heavy chain variable region; (vi) a linker peptide comprising a 2A peptide; (vii) optionally a signal peptide; and (viii) a light chain comprising a light chain variable region; wherein the first heavy chain comprises an antigen-binding region capable of binding to a first antigen; the heavy chain variable region and the light chain variable region of the second heavy chain form an antigen-binding region capable of binding to a second antigen; The nucleic acid product, wherein the first heavy strand and the second heavy strand are bound to each other using knob-into-hole technology.
2. The peptide linker has the following characteristics: (i) having a 2A peptide derived from a virus selected from the group consisting of foot and mouth disease virus, equine rhinitis A virus, porcine teschovirus-1, and Thosea asigna virus; (ii) further comprising a protease recognition site at the N-terminus of the 2A peptide, the protease recognition site being, in particular, a furin recognition site; (iii) comprises an amino acid sequence according to SEQ ID NO:
25. The nucleic acid product of claim 1, having one or more of the following:
3. (i) a more uniform cellular production of the polypeptide chains of the antibody construct compared to cellular production of the polypeptide chains of the antibody construct using a nucleic acid product, in which each polypeptide chain of the antibody construct is encoded in a separate open reading frame, optionally in which the amount of mRNA encoding the different polypeptide chains of the antibody in the cell does not differ by more than a factor of 10; and / or (ii) a relative amount of correctly assembled antibody constructs following expression of the polypeptide chains of the antibody construct that is higher compared to the relative amount of correctly assembled antibody constructs following expression of the polypeptide chains of the antibody construct using a nucleic acid product, wherein each polypeptide chain of the antibody construct is encoded in a separate open reading frame, optionally wherein the relative amount of correctly assembled antibody constructs following expression of the polypeptide chains of the antibody construct is at least 10 percentage points higher than the relative amount of correctly assembled antibody constructs using a nucleic acid product, wherein each polypeptide chain is encoded in a separate open reading frame. The nucleic acid product of claim 1 or 2.
4. 4. The nucleic acid product of any one of claims 1 to 3, wherein the open reading frame encoding two or more polypeptide chains of the antibody construct is part of an expression cassette enabling expression of the open reading frame.
5. The nucleic acid product according to any one of claims 1 to 4, wherein the vector nucleic acid is a plasmid.
6. A host cell comprising a nucleic acid product according to any one of claims 1 to 5.
7. 7. The host cell according to claim 6, which is a mammalian cell, in particular a human or rodent cell, in particular a CHO cell.
8. (a) providing a host cell according to claim 6 or 7, (b) culturing said host cells in cell culture under conditions that allow the production of an antibody construct; (c) obtaining the antibody construct from the cell culture; and (d) optionally treating the antibody construct A method for producing said antibody construct comprising:
9. - step (c) comprises isolating the antibody construct and / or separating the antibody construct from the remaining components of the cell culture; and / or - step (d) comprises formulating said antibody construct as a pharmaceutical composition; The method of claim 8.
10. (i) the polypeptide chains of the antibody product are produced more uniformly compared to production of the polypeptide chains of the antibody construct using a nucleic acid product, in which each polypeptide chain of the antibody construct is encoded in a separate open reading frame, and optionally the amount of mRNA encoding the different polypeptide chains of the antibody construct in the cell does not differ by more than a factor of 10; and / or (ii) the relative amount of correctly assembled antibody constructs is higher compared to production of said antibody constructs using a nucleic acid product in which each polypeptide chain of said antibody construct is encoded in a separate open reading frame, optionally the relative amount of correctly assembled antibody constructs is at least 10 percentage points higher than the relative amount of correctly assembled antibody constructs using a nucleic acid product in which each polypeptide chain is encoded in a separate open reading frame; 10. The method according to claim 8 or 9.
11. Use of a nucleic acid product according to any one of claims 1 to 5 or a host cell according to claim 6 or 7 for the production of an antibody construct.
12. A method for producing a host cell according to claim 6 or 7, comprising introducing a nucleic acid product according to any one of claims 1 to 5 into a host cell.
